“The good news is, we can’t kill you trying to save you. You showed up fit to fight.” Still in shock of recent events, Loriana Hernandez-Aldama tried to process the words of world-renowned oncologist Dr. Mark Levis. In such a short period of time in January 2014, her life had completely changed. Just a few days earlier, Loriana, a married mother and TV news anchor with a successful career in Austin and Dallas, Texas, was excitedly working with her fertility doctor to have another baby. But a precautionary blood test before a traditional embryo transfer revealed a disheartening diagnosis of AML Leukemia, an aggressive blood cancer. At the advice of her doctor and healthcare connections, she kissed her then 2-year-old son, Gabriel, goodbye, and boarded a plane to Johns ...
Unfortunately, Latino men have lower cancer screening rates than their White peers. Only 30% of Latino men received a PSA test for prostate cancer in the past year, compared to 37% of White men. Colorectal cancer screening was lower in Latinos (49%) than Whites (58%), too. To address this issue, you’re invited to join our webinar — Men, Why Should You Get Screened for Cancer? — at 2 p.m. CT on June 9, 2022. This Zoom webinar will feature guest speakers and patient advocates to help health care professionals and the Latino public understand the cultural and other barriers to screening, demystify screening tests, and share stories of Latino men's screening and cancer survival. This is the fourth webinar of a new series, “Let’s Address Health Equity Together.” The ...
Por Tatiana Holanda
Sobreviviente de cáncer brasileña en San Antonio No veo al cáncer como un oponente "Lo veo como un maestro". Esa es la frase que resume mi historia. A la edad de 33 años, luego de los exámenes, se detectó un bulto en la mama izquierda de 2 cm, en el examen de ultrasonido se clasificó como Birads 4 con indicación de biopsia. En junio de 2019, con el resultado en la mano, se confirmó que tenía cáncer de mama triple negativo. Al principio, desesperación, luego angustia y ansiedad. Hubo 40 días de espera entre el diagnóstico y el inicio del tratamiento. Tuve que sacar fuerzas de algún lado, en ese momento mi hijo Rafael tenía 1 año. Cuando descubrí la enfermedad, pensé: tanto le pedí a Dios un hijo y ¿qué voy a hacer ahora frente al ...
March is Colorectal Cancer Awareness Month. This cancer can affect anyone, but older Latinos may be particularly at risk. Know the facts about colorectal cancer, tips for screening and preventions, and how we can help researchers studying cancer.
What Should I Know About Colorectal Cancer?
Colorectal cancer is the disease of the colon and/or rectum. “Most cases of colorectal cancer occur in people ages 45 and older, but the disease is increasingly affecting younger people. Each year, about 150,000 Americans are diagnosed with this disease and more than 50,000 die,” according to the Colorectal Cancer Alliance. Many people in the early stages of colorectal cancer do not experience symptoms. However, symptoms might develop later on in the disease. Mayo Clinic lists ...
Latinos are a dynamic, diverse, rising population. But cancer threatens the future health of the U.S. Latino population. This is why our Salud America! team at the Institute for Health Promotion Research (IHPR) at UT Health San Antonio created a new video, "Latino Cancer: ¿Sabía Usted? (Did You Know?)," to describe the state of Latino cancer disparities and highlight the inequities behind them. The video debuted at the 2022 Advancing the Science of Cancer in Latinos conference. "The conference helped focus on a key underlying issue – health equity. Health equity is where everyone has a fair, just opportunity to be their healthiest," said Dr. Amelie G. Ramirez, leader of the conference and director of Salud America! and the IHPR. "True change starts when we focus on solving ...
With 1 in 3 Latinos facing a cancer diagnosis in their lifetime, UT Health San Antonio is hosting the 2022 Advancing the Science of Cancer in Latinos in-person conference on Feb. 23-25 at the Westin Riverwalk, 420 W. Market St, in San Antonio, Texas. The biennial conference is expected to draw 200 researchers, oncologists, physicians, community leaders, and students for an open dialogue on research advancements and actions to translate basic research into clinical best practices, effective community interventions, system-change advocacy, and professional training to eliminate cancer disparities in Latinos. The first Advancing the Science of Cancer in Latinos conferences in 2018 and 2020 united 80 guest speakers and over 600 attendees from 25 states, from D.C and New York to ...
Cancer survivors face the possibility that cancer will come back after treatment. Clinical trials are studies that help researchers learn more to help slow, manage, and treat cancer, as well as prevent cancer recurrence. If you have had bladder cancer, you can volunteer for a bladder cancer prevention clinical trial that is studying encapsulated rapamycin (eRapa) and its ability to reduce the risk of bladder cancer recurrence. This trial is led by researchers across Texas, including UT Health San Antonio, UT Southwestern Medical Center, and South Texas Veterans Health Care System, to explore new ways to prevent bladder cancer from coming back. “Unfortunately, people who’ve had bladder cancer have a high risk of developing a second bladder cancer,” said Dr. Amelie ...
Stomach cancer, also called gastric cancer, disproportionately impacts Latinos. In fact, U.S. Latino men and women are twice as likely as their White peers to develop invasive gastric cancer, according to a 2021 report. But little is known about regional differences. That is why Dr. Dorothy Long Parma of UT Health San Antonio and her colleagues conducted a study to analyze gastric cancer rates for Latinos in South Texas, Texas, and the United States. "We found that overall stomach cancer incidence rates in Texas and South Texas were higher in Latinos than in non-Latino Whites, despite lower frequencies in the state and South Texas region compared to the United States," said Long Parma, assistant professor/research at the Institute for Health Promotion Research (IHPR) in the ...
The patient economic burden for cancer in the U.S. was $21.09 billion, according to the Annual Report to the Nation on the Status of Cancer in JNCI: The Journal of the National Cancer Institute. “[This total is] made up of patient out-of-pocket costs of $16.22 billion and patient time costs of $4.87 billion,” according to the annual report. As technology, cancer research, and medicine advances, the effectiveness of therapy treatments only seem to proliferate. Though this is good news, the reality is that modern cancer treatments are a financial burden to people of color, who also face barriers to equitable cancer care. Latinos in particular face obstacles such as poor health literacy, concerns about test efficacy, and language and cultural beliefs related to cancer, ...
